<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011675'>Arrhythmia</z:hpo> risk stratification with regard to prophylactic implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapy was investigated in the Marburg <z:hpo ids='HP_0001638'>Cardiomyopathy</z:hpo> Study, which revealed left ventricular ejection fraction to be the only significant independent <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> risk predictor in a relatively large <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>) patient population </plain></SENT>
<SENT sid="1" pm="."><plain>Based of the favorable results of the SCD-HeFT Trial, prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy became a class I indication for patients with <z:chebi fb="20" ids="15767">DCM</z:chebi>, NYHA class II or III <z:hpo ids='HP_0001635'>heart failure</z:hpo> and a left ventricular ejection fraction ≤ 35% despite optimized medical therapy </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy combined with cardiac resynchronization became standard treatment in <z:chebi fb="20" ids="15767">DCM</z:chebi> patients with complete <z:hpo ids='HP_0011713'>left bundle branch block</z:hpo> and an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> indication according to SCD-HeFT criteria </plain></SENT>
<SENT sid="3" pm="."><plain>Unresolved issues of prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in <z:chebi fb="20" ids="15767">DCM</z:chebi> include a high number to treat in order to save one patient from <z:hpo ids='HP_0001699'>sudden death</z:hpo> due to difficult <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> risk stratification which is largely based on reduced left ventricular ejection fraction </plain></SENT>
<SENT sid="4" pm="."><plain>Second, optimal timing of prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implant remains difficult, because a significant but unpredictable number of <z:chebi fb="20" ids="15767">DCM</z:chebi> patients show a marked improvement of left ventricular function during follow-up, thus, averting the need prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy is associated with a considerable complication rate with painful inappropriate shocks and lead-related problems being the most frequent complications during long-term follow-up </plain></SENT>
</text></document>